Taysha Gene Therapies Joins the Rare Disease Company Coalition
May 19 2021 - 7:00AM
Business Wire
Joined an alliance of life science companies
dedicated to rare disease therapy development to support advocacy
for policies that will improve processes for timely and
cost-effective delivery of treatments
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric,
pivotal-stage gene therapy company focused on developing and
commercializing AAV-based gene therapies for the treatment of
monogenic diseases of the central nervous system (CNS) in both rare
and large patient populations, today announced that it has joined
the newly formed Rare Disease Company Coalition, a
first-of-its-kind alignment of life sciences companies committed to
discovering, developing and delivering rare disease treatments for
the patients they collectively serve.
“Taysha is honored to be a founding member of the Rare Disease
Company Coalition,” said RA Session II, President, Founder and
Chief Executive Officer of Taysha. “As we grow to become a leader
in the development of gene therapies for the treatment of rare
diseases, we have a responsibility to our community, especially to
our patients and their families, to advocate for more effective
policies and regulations that will encourage innovation around
potentially life-saving therapies. We look forward to working with
this impressive group of companies to drive awareness about the
specific challenges of rare disease research and development and
promote solutions that will support timely delivery of valuable
treatments to patients.”
As an education and advocacy-focused coalition of companies, the
shared goal of the Coalition is to inform policymakers of the
unique circumstances of the rare disease company business model,
specifically focusing on the unique circumstances involved in
developing and bringing to market therapies for small and
differentiated patient population sizes. The Coalition will
advocate for policy and regulatory frameworks that account for and
recognize the distinct considerations of life science companies
operating in the rare disease space and the impact it has on
delivering innovative therapies to the patients they serve.
Founding members of the Coalition include:
- Acceleron Pharma
- Aeglea BioTherapeutics
- Agios Pharmaceuticals
- Alnylam Pharmaceuticals
- Harmony Biosciences
- Orchard Therapeutics
- Orphazyme US, Inc.
- Sarepta Therapeutics
- Taysha Gene Therapies
- Ultragenyx Pharmaceutical
In the coming month, the Coalition will engage with policy
stakeholders on potentially impactful drug and healthcare policies
and regulations currently under discussion, including prescription
drug pricing, to highlight the consequences that blanket
legislation can have on continued innovation for rare disease
treatments.
About the Rare Disease Company Coalition
The Rare Disease Company Coalition represents life science
companies committed to discovering, developing and delivering rare
disease treatments for the patients we serve. As an education and
advocacy-focused coalition of companies, our goal is to inform
policymakers of the unique challenges and promises of rare disease
drug discovery, development and manufacturing for small population
sizes in order for critical innovation to continue. To achieve this
goal, we will use our unified voice to advocate for long-term,
consistent, equitable and sustainable government policies that
enable life science companies to continue to bring hope and provide
access to approved treatments to people living with rare diseases.
For more information, please visit www.rarecoalition.com.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to
eradicate monogenic CNS disease. With a singular focus on
developing curative medicines, we aim to rapidly translate our
treatments from bench to bedside. We have combined our team’s
proven experience in gene therapy drug development and
commercialization with the world-class UT Southwestern Gene Therapy
Program to build an extensive, AAV gene therapy pipeline focused on
both rare and large-market indications. Together, we leverage our
fully integrated platform—an engine for potential new cures—with a
goal of dramatically improving patients’ lives. More information is
available at www.tayshagtx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210519005325/en/
Company Contact: Kimberly Lee, D.O. SVP, Corporate
Communications and Investor Relations Taysha Gene Therapies
klee@tayshagtx.com Media Contact: Carolyn Hawley Canale
Communications carolyn.hawley@canalecomm.com
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Jul 2023 to Jul 2024